Software support for ‘doing the right thing right’

Joseph L. Dorsey

doi:10.1160/TH08-12-0820

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 413-414
DOI: 10.1160/TH08-12-0820

Editorial Focus

Schattauer GmbH

Software support for ‘doing the right thing right’

Joseph L. Dorsey

Harvard Vanguard Medical Associates, Internal/Hospital Medicine, Walpole, Massachusetts, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Mant J, Hobbs FDR, Fletcher K. et al. Warfarin vs. Aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA): a Randomised controlled trial. Lancet 2007; 370: 493-503.
2 Ansell J, Caro JJ, Salas M. et al. Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. Am J Med Qual 2007; 22: 327-333.
3 Centers for Medicare & Medicaid Services (CMS): Decision memo for prothrombin time (INR) monitor for home anticoagulation management (CAG-00087R). 03/19/08.
4 Ansell J, Hirsh J, Hylek E. et al. Table 7 in Pharmacology and management of the vitamin K antagonists. Chest 2008; 133: 183S.
5 Garcia DA, Witt DM, Hylek E. et al. Delivery of optimized anticoagulant therapy: Consensus statement from The Anticoagulation Forum. Ann Pharmacother 2008; 42: 978-988.
6 Oertel LB, Mungall D. Software applications in anticoagulation management. In: Managing oral anticoagulation therapy: clinical and operational guidelines. 2005. Wolters Kluwer Health, Inc.;
7 Poller L, Keown M, Ibrahim S. et al. A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost 2009; 101: 487-494.
8 Campbell PM, Radensky PW, Denham CR. Economic analysis of systematic anticoagulation management vs. routine medical care for patients on oral warfarin therapy. Dis Manag Clin Outcomes 2000; 2: 1-8.
9 Lafata JE, Martin SA, Kaatz S. et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31-37.
10 Lesko LJ. Response letter from FDA (to a letter to FDA from AC Forum BOD). Anticoagulation Forum 2007; 11: 1-5.
11 Shurin SB, Nabel LG. Pharmacogenomics-ready for prime time?. New Engl J Med 2008; 358: 1061-1063.